

CLAIMS

- 5 1. A method of protecting a solid-state protein from ionizing radiation which comprises combining said protein with a radiation-protecting amount of a methoxysalicylaldehyde derivative prior to exposing said protein to said ionizing radiation.
- 10 2. A method according to claim 1 wherein said methoxysalicylaldehyde derivative is 3-methoxysalicylaldehyde.
- 15 3. A method of protecting a solid-state protein from ionizing radiation which comprises combining said protein with radiation-protecting amounts of a methoxysalicylaldehyde derivative and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid prior to exposing said protein to said ionizing radiation.
- 20 4. A method according to claim 3 wherein said methoxysalicylaldehyde derivative is 3-methoxysalicylaldehyde.
- 25 5. A method of protecting a solid-state protein from ionizing radiation which comprises combining said protein with radiation-protecting amounts of a methoxysalicylaldehyde derivative and isopropanol prior to exposing said protein to said ionizing radiation.
6. A method according to claim 5 wherein said methoxysalicylaldehyde derivative is 3-methoxysalicylaldehyde.
7. A formulation comprising a solid-state protein and a methoxysalicylaldehyde derivative.
8. A formulation according to claim 7 wherein said protein is a drug.
- 30 9. A formulation according to claim 7 wherein said methoxysalicylaldehyde derivative is 3-methoxysalicylaldehyde.

9/22/21

00005016-024204

9/22/21

10. A formulation according to claim 7 wherein said methoxysalicylaldehyde derivative comprises at least about 0.1% by weight of said formulation.

11. A formulation according to claim 10 wherein said methoxysalicylaldehyde derivative comprises from about 2.9% to about 8.0% by weight of said formulation.

12. A formulation comprising a solid-state protein, a methoxysalicylaldehyde derivative, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.

13. A formulation according to claim 12 wherein said protein is a drug.

14. A formulation according to claim 12 wherein said methoxysalicylaldehyde derivative is 3-methoxysalicylaldehyde.

15. A formulation according to claim 12 wherein said methoxysalicylaldehyde derivative comprises at least about 0.1% by weight of said formulation, and said 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid comprises at least about 0.1% by weight of said formulation.

16. A formulation according to claim 15 wherein said methoxysalicylaldehyde derivative comprises from about 2.9% to about 8.0% by weight of said formulation, and said 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid comprises from about 0.1% to about 1.0% by weight of said formulation.

17. A formulation comprising a solid-state protein, a methoxysalicylaldehyde derivative, and isopropanol.

18. A formulation according to claim 17 wherein said protein is a drug.

19. A formulation according to claim 17 wherein said methoxysalicylaldehyde derivative is 3-methoxysalicylaldehyde.

According to claim 17 wherein said methoxysalicylaldehyde derivative comprises from about 2.9% to about 8.0% by weight of said formulation and said 2-hydroxybenzoic acid comprises from about 0.1% to about 0.5% by weight of said formulation.

According to claim 17 wherein said methoxysalicylaldehyde derivative comprises a methoxysalicylaldehyde derivative and said 2-hydroxybenzoic acid comprises from about 0.1% to about 0.5% by weight of said formulation.

According to claim 22 wherein said methoxysalicylaldehyde derivative comprises a methoxysalicylaldehyde derivative and said 2-hydroxybenzoic acid comprises from about 0.1% to about 0.5% by weight of said formulation.

5

10

15

~~use of  
ectant~~

[illegible]